BioCentury
ARTICLE | Clinical News

Introgen gene therapy enters Phase III

June 8, 2000 7:00 AM UTC

Introgen (Austin, Texas) and partner Aventis (AVE) began enrollment of a 240-patient Phase III trial of RPR/ INGN 201 adenoviral p53 tumor suppressor gene therapy to treat recurrent/refractory squamou...